Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23117716)

1.

[Scope of the latest RE-LY substudies: clinical implications].

Ruiz-Giménez Arrieta N.

Rev Clin Esp. 2012 Mar;212 Suppl 2:4-14. doi: 10.1016/S0014-2565(12)70013-9. Spanish.

PMID:
23117716
2.

Dabigatran etexilate in atrial fibrillation.

Vora A.

J Assoc Physicians India. 2013 Dec;61(12):900-2. Review.

PMID:
24968547
3.

[Chinese practical guide of dabigatran etexilate for stroke prevention in patients with non-valvular atrial fibrillation].

Working Group on Thrombosis of Chinese Journal of Cardiology.

Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Mar;42(3):188-92. Chinese. No abstract available.

PMID:
24831473
4.

Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.

Waks JW, Zimetbaum PJ.

Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1461-71. doi: 10.1586/14779072.2013.849572. Epub 2013 Oct 23.

PMID:
24147516
5.

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.

Clemens A, Fraessdorf M, Friedman J.

Vasc Health Risk Manag. 2013;9:599-615. doi: 10.2147/VHRM.S49830. Epub 2013 Oct 11. Review.

6.

[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].

Szapary L, Fehér G, Bosnyák E, Deli G, Csécsei P.

Ideggyogy Sz. 2013 May 30;66(5-6):165-74. Review. Hungarian.

PMID:
23909016
7.

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients.

Ellis CR, Kaiser DW.

Vasc Health Risk Manag. 2013;9:341-52. doi: 10.2147/VHRM.S28271. Epub 2013 Jul 9. Review.

8.

Stroke prevention in atrial fibrillation patients with chronic kidney disease.

Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ.

Can J Cardiol. 2013 Jul;29(7 Suppl):S71-8. doi: 10.1016/j.cjca.2013.04.005. Review.

PMID:
23790601
9.

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S.

Circulation. 2013 Jul 16;128(3):237-43. doi: 10.1161/CIRCULATIONAHA.112.001139. Epub 2013 Jun 14.

10.

Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.

Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G, Froehlich JB, Goldhaber SZ.

Am J Cardiol. 2013 Aug 1;112(3):387-9. doi: 10.1016/j.amjcard.2013.03.046. Epub 2013 May 3.

PMID:
23647794
11.

Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.

Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY.

J Am Coll Cardiol. 2013 Jun 4;61(22):2264-73. doi: 10.1016/j.jacc.2013.03.020. Epub 2013 Apr 3.

12.

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC.

Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.

13.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Berman JP, Halperin JL.

Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Review.

PMID:
23466966
14.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
15.

Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.

Dogliotti A, Paolasso E, Giugliano RP.

Clin Cardiol. 2013 Feb;36(2):61-7. doi: 10.1002/clc.22081. Epub 2013 Jan 21. Review.

PMID:
23338902
16.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
17.

Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.

Wouters H, Thijs V, Annemans L.

J Med Econ. 2013;16(3):407-14. doi: 10.3111/13696998.2013.766200. Epub 2013 Jan 22.

PMID:
23320796
18.

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S.

Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.

19.

Role of new drugs for management of atrial fibrillation.

Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM.

Ann Pharmacother. 2012 Dec;46(12):1656-70. doi: 10.1345/aph.1R155. Epub 2012 Dec 18. Review.

PMID:
23249869
20.

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators.

Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk